Abstract
Autoimmune liver diseases (AILDs) are complex conditions, which arise from the interaction between a genetic susceptibility and unknown environmental triggers. They represent a relevant cause of liver failure and liver transplantation worldwide. As a testimony of our progress in understanding the biology of AILDs and the disease progression is the overall median survival which has increased over the last decade. However, there are still major challenges such as the lack of therapies and surveillance strategies in primary sclerosing cholangitis (PSC), the management and treatment of non-responders to first-line therapies in primary biliary cholangitis (PBC) and the need for tailoring immunosuppressive drugs in autoimmune hepatitis (AIH). The different disease course and treatment response in patients with AILDs might be related to a heterogeneous genetic background between individuals which translates in a heterogeneous clinical phenotype. Thus, it becomes essential to personalise management and treatment based on specific risk profiles, e.g. low-risk and high-risk, based on genetic and molecular signatures. It is now possible, thanks to the development of large-scale AILDs patient cohorts, that such diseases can be analysed usi...Continue Reading
Citations
May 18, 2019·Journal of Digestive Diseases·James B Maurice, Douglas Thorburn
Apr 13, 2020·Liver International : Official Journal of the International Association for the Study of the Liver·Lars BossenPietro Invernizzi
Aug 7, 2020·Liver International : Official Journal of the International Association for the Study of the Liver·Domenico AlvaroPietro Invernizzi
Apr 23, 2020·Frontiers in Medicine·Alessio GerussiPietro Invernizzi
Aug 7, 2020·Journal of Clinical Medicine·Emidio ScarpelliniLudovico Abenavoli
Apr 2, 2019·Expert Opinion on Pharmacotherapy·Andrea A Gossard, Keith D Lindor
Nov 5, 2019·Frontiers in Pharmacology·Xiaoli FanLi Yang
Dec 1, 2020·Expert Opinion on Investigational Drugs·Eric M Gochanour, Kris V Kowdley
Nov 28, 2019·Annals of Hepatology·Alessio GerussiPietro Invernizzi
Mar 13, 2021·Therapeutic Drug Monitoring·Stein BerganLoralie J Langman
Aug 11, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Alessio GerussiUNKNOWN Italian PBC Study Group and the GLOBAL PBC Study Group
Jul 17, 2021·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Clara BalsanoUNKNOWN Special Interest Group (SIG) Artificial Intelligence and Liver Diseases; Italian Association for the Study of the Liver (AIS
Dec 25, 2021·Liver International : Official Journal of the International Association for the Study of the Liver·Alessio GerussiPietro Invernizzi